EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overview of Pharmacological Therapies for Diffuse Tenosynovial Giant Cell Tumor

Antonia Stamatiou, Tu Nguyen-Ngoc, Laureline Wetterwald, Ana-Maria Dolcan, Giovanni Dei Tos, Stephane Cherix, Patrick Omoumi, Antonia Digklia

Future Pharmacology · 01.12.2023 · 3 (4) · 926-937

DOI: 10.3390/futurepharmacol3040056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Pharmacology, online erschienen am 01.12.2023. Verfasst von Antonia Stamatiou und 7 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tenosynovial giant cell tumor (TGCT) is a rare and locally aggressive benign tumor arising from the synovium of joints, bursae, and tendon sheaths. It is classified into localized (L-TGCT) and diffuse (D-TGCT) forms based on the extent of involvement. Surgical resection is the primary treatment, though achieving a definitive cure remains challenging due to the high recurrence rates, especially in D-TGCT. Systemic therapies targeting the CSF1-CSF1R axis have emerged as promising treatment options. CSF1R tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, pexidartinib, and vimseltinib, alongside anti-CSF1R antibodies like emactuzumab, cabiralizumab, and lacnotuzumab, have shown encouraging results in managing TGCT, particularly when surgery is not feasible or poses significant morbidity. Other potential therapies, including local treatments and anti-inflammatory drugs, are being explored for TGCT management. This review provides an overview of systemic treatment options for D-TGCT, highlighting emerging therapeutic modalities and their potential implications. Effective management is crucial due to TGCT’s significant morbidity despite its non-life-threatening nature, necessitating novel approaches to improve patient prognosis and quality of life.

Zitieren

APA

Stamatiou, A., Nguyen-Ngoc, T., Wetterwald, L., Dolcan, A., Tos, G. D., Cherix, S., Omoumi, P., & Digklia, A. (2023). Overview of Pharmacological Therapies for Diffuse Tenosynovial Giant Cell Tumor. Future Pharmacology, 3(4), 926-937. https://doi.org/10.3390/futurepharmacol3040056

Vancouver

Stamatiou A, Nguyen-Ngoc T, Wetterwald L, Dolcan A, Tos GD, Cherix S, et al. Overview of Pharmacological Therapies for Diffuse Tenosynovial Giant Cell Tumor. Future Pharmacology. 2023;3(4):926-937. doi:10.3390/futurepharmacol3040056

BibTeX
@article{Stamatiou2023,
  author = {Stamatiou, Antonia and Nguyen-Ngoc, Tu and Wetterwald, Laureline and Dolcan, Ana-Maria and Tos, Giovanni Dei and Cherix, Stephane and Omoumi, Patrick and Digklia, Antonia},
  title = {Overview of Pharmacological Therapies for Diffuse Tenosynovial Giant Cell Tumor},
  journal = {Future Pharmacology},
  year = {2023},
  volume = {3},
  number = {4},
  pages = {926--937},
  doi = {10.3390/futurepharmacol3040056}
}
Kostenlos starten →